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Abstract
Background: Alpha-lactalbumin (a-LA) is a calcium-bound mammary gland-specific protein that is found in milk. This protein is a
modulator of b1,4-galactosyltransferase enzyme, changing its acceptor specificity from N-acetyl-glucosamine to glucose, to
produce lactose, milk’s main carbohydrate. When calcium is removed from a-LA, it adopts a molten globule form, and this form,
interestingly, when complexed with oleic acid (OA) acquires tumoricidal activity. Sucha complex madefrom human a-LA (hLA) is
known as HAMLET (Human A-lactalbumin Made Lethal to Tumor cells), and its tumoricidal activity has been well established.
Methodology/Principal Findings: In the present work, we have used site-specific labeling, a technique previously
developed in our laboratory, to label HAMLET with biotin, or a fluoroprobe for confocal microscopy studies. In addition to
full length hLA, the a-domain of hLA (aD-hLA) alone is also included in the present study. We have engineered these
proteins with a 17–amino acid C-terminal extension (hLA-ext and aD-hLA-ext). A single Thr residue in this extension is
glycosylated with 2-acetonyl-galactose (C2-keto-galactose) using polypeptide-a-N-acetylgalactosaminyltransferase II
(ppGalNAc-T2) and further conjugated with aminooxy-derivatives of fluoroprobe or biotin molecules.
Conclusions/Significance: We found that the molten globule form of hLA and aD-hLA proteins, with or without C-terminal
extension, and with and without the conjugated fluoroprobe or biotin molecule, readily form a complex with OA and
exhibits tumoricidal activity similar to HAMLET made with full-length hLA protein. The confocal microscopy studies with
fluoroprobe-labeled samples show that these proteins are internalized into the cells and found even in the nucleus only
when they are complexed with OA. The HAMLET conjugated with a single biotin molecule will be a useful tool to identify
the cellular components that are involved with it in the tumoricidal activity.
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Introduction
Alpha-lactalbumin (a-LA) is a 14 kDa, Ca
2+-binding milk
protein, synthesized in the secretory cells of lactating mammary
glands. Its main function is to interact with b1,4-galactosyltrans-
ferase-1 (b4Gal-T1) to form lactose synthase complex (LS). By
binding to b4Gal-T1, a-LA changes the acceptor specificity of
b4Gal-T1 from GlcNAc to glucose, to synthesize lactose, which is
the primary carbohydrate in milk of most mammalian species [1].
Due to the similarities in gene structure and protein sequences, it
has been proposed that a-LA and c-type lysozyme have evolved
from the same gene [2]. As in the protein structure of c-type
lysozyme, a-LA has 4 helices contained in the a-domain and b-
sheets that form a b-domain. However, a-LA has a tightly bound
Ca
2+ in the calcium-binding loop. Removal of Ca
2+ leads to a
molten globule state of a-LA [3,4]. X-ray crystallographic studies
on the complex of a-LA with b4Gal-T1 [5], together with enzyme
kinetics studies have led to an understanding of the modulation
mechanism in the LS complex [6,7].
a-LA is expressed only in mammals and in the mammary gland
during lactation to function as a lactose synthase complex. However,
some breast cancer cells have been found to express a-LA protein [8-
10]; a-LA has also been shown to cause apoptosis of mouse and
human mammary epithelial cell lines [11] as well as of fur seal
primary mammary cells, identifying it as a milk factor that regulates
involution [12]. Small but detectable amounts of a-LA have been
found during the early gestation phase in rat mammary gland [13].
Wehave alsocloned the humana-LA froma cDNA libraryprepared
from the non-lactating mammary gland that lactated previously and
have used in the present studies. Thus, these studies indicate that a-
LA has been at least transcribed in the breast tissues at various stages,
though its function at those stages is not known.
Since 1995, pioneering work by Dr. Svanborg’s group has shown
that a-LA in the molten globule state complexes with oleic acid
(OA), acquiring apoptotic properties toward tumor and immature
cells, but not toward differentiated cells [14–16]. Extensive studies
on the biological property of the complex, named HAMLET by Dr.
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lethal to tumor cells, have shown that it induces mitochondrial
depolarizationand cytochrome c release [17] and that the apoptotic
response triggered by HAMLET is independent of caspase
inhibition, p53 status, and Bcl-2 over expression [18]. In addition,
HAMLET-induced changes are compatible with macroautophagy
[19]. Other studies suggested perturbation of the proteasome
structure [20] and lipid membrane integrity [21]. Besides the broad
evidence of HAMLET’s anti-tumor activity, the mechanism(s) of
cytotoxicity has not yet been elucidated [22].
After having first cloned a-LA and b4Gal-T1 genes [23,24] and
studied their molecular interactions [5–7], here we have initiated
the structure-based analysis of HAMLET using our site-specific
labeling technique [25,26]. We have reproduced the previously
described results by Svanborg et al., [14–16], showing that the
molten globule a-LA in complex with OA kills many different
tumor cells, but not untransformed or normal cells. We have
designed a human a-LA (hLA) and an a-domain of hLA (aD-hLA)
with a polypeptide tag at the C-terminal end, hLA-ext and aD-
hLA-ext, respectively, which can be specifically glycosylated with
ppGalNAc-T2, transferring a modified galactose with a chemical
handle (C2-keto-galactose), as described previously [25,26], that
can be further labeled with aminooxy-Alexa Fluor 488. We show
here that the tumoricidal complex derived from the site-specific-
labeled hLA-ext or aD-hLA-ext also kills many tumor cells and
have used these labeled proteins for cell imaging.
Results
Protein expression and folding
The recombinant hLA (124 aa) and hLA with a 17 amino acid
C-terminal extension (hLA-ext) (Figure 1A) were expressed in E.
coli as inclusion bodies and folded in vitro as described previously
[27,28]. The near UV CD spectrum show that these proteins exist
in their native state with significant tertiary structure (Figure 2A).
However when the bound calcium ion is removed by dialysis
against EGTA, they adopt a molten globule structure as judged by
its near UV spectrum (Figure 2B). The native a-LA contains alpha
(a-) and beta (b-) domains (Figure 1A, 3). The alpha-domain (83
aa) comprises of the N-terminal region, residues 1 to 39, and the
C-terminal region, residues 81 to 124, of the human LA. We have
engineered the a-domain-form of hLA with 86 amino acids (MW
9.7 kDa) (aD-hLA), in which the beta domain has been removed
and both fragments of the N- and the C-terminal region were
linked by three glycine residues (Figure 1B) [29]. The a-domain
hLA protein with and without the C-terminal extension were
‘‘refolded’’ in the absence of calcium salt and purified by
ammonium sulfate precipitation. The near UV CD spectrum of
these proteins shows that they exist in the molten globule form
(Figure 2B).
Although DNA sequencing of the hLA-ext and aD-hLA-ext
protein genes confirmed the presence of the C-terminal extension,
its presence in these proteins could be clearly seen from the SDS-
PAGE gels as these proteins have a higher molecular weight
compared to their respective native protein (Figures 3A and C).
These gels further showed that upon the loss of the C-terminal
extension peptide with thrombin protease treatment their
molecular weight is found similar to their respective native protein
(Figure 3A and C). Since the molecular weight of the released C-
terminal polypeptide is only 1337 Da it could not be observed on
any SDS-PAGE gel, therefore, a MALDI-TOF spectroscopic
analysis of these thrombin treated samples was carried out. Such
analysis shows a release of correct molecular weight peptide upon
the treatment of thrombin from these proteins (Figure 3B),
confirming the presence of thrombin cleavable C-terminal
extension peptide in these proteins.
Site-specific labeling of hLA-ext and aD-hLA-ext protein
molecules
Using the ppGalNAc-T2 enzyme, C2-keto-galactose from
UDP-C2-keto-Gal was transferred to the single Thr residue,
located in the polypeptide extension of the native hLA-ext protein
(Figure 4A & B). MS analysis of the thrombin cleaved peptide from
the glycosylated hLA-ext protein showed an increase in molecular
mass by 201 Da that corresponds to a single C2-keto-gal sugar
moiety, thus confirming the presence of a single sugar moiety in
the C-terminal extension peptide (Figure 4B). The glycosylated
Figure 1. Schematic diagram of the hLA and aD-hLA proteins with C-terminal extension. (A) hLA (protein sequence acc. No J00270) and
hLA-ext proteins with the crystal structure of hLA (far right) (pdb 1a4v) showing alpha and beta domains. (B) aD-hLA and aD-hLA-ext proteins with
the corresponding alpha domain structure (model) (far right). Since the alpha domain is comprised of N-terminal residues, 1 to 39, and the C-terminal
residues, 81 to 124, of hLA (cyan colored), a three residue glycine linker was used to fuse the N-terminal and C-terminal fragments to construct the
alpha domain form of the protein (aD-hLA) where beta domain is removed. A 17-amino-acid extension containing a thrombin cleavage site and a Thr
residue (substrate for ppGalNAcT2 enzyme), was engineered at the C-terminal domain of hLA (A, hLA-ext) and aD-hLA (B, aD-hLA-ext).
doi:10.1371/journal.pone.0026093.g001
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PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e26093Figure 2. Tertiary structure studied with near UV CD spectra. (A) The near UV spectra of the native refolded hLA and hLA-ext proteins show
positive and negative peaks indicating the CD bands arising from aromatic amino acids and suggest the presence of tertiary structure. When these
proteins are treated with a chelating agent to remove Ca
2+ ion, these proteins acquire a molten globule state (B). Interestingly the aD-hLA and aD-
hLA-ext show similar near UV CD spectra as molten globule hLA.
doi:10.1371/journal.pone.0026093.g002
Figure 3. Incorporation of a polypeptide tag to full length hLA and aD-hLA proteins. Schematic representation of the C-terminal extension
of 17 amino acids engineered on hLA showing the acceptor Thr residue for the site-specific labeling and the thrombin cleavage site. (A) SDS-PAGE
analyses of purified hLA, hLA-ext, with and without thrombin treatment. To confirm the presence of the C-terminal extension peptide, the protein
was treated with thrombin. The mobility of hLA-ext treated with thrombin is comparable to wild-type hLA. (B) Since the molecular weight of the
released C-terminal polypeptide is only 1337 Da it could not be observed on any SDS-PAGE gel. However, MALDI-TOF spectroscopic analysis of the
thrombin treated samples showed a release of a correct molecular weight peptide from the proteins carrying the C-terminal extension peptide. (C)
The protein samples aD-hLA and aD-hLA-ext with and without Thrombin treatment were analyzed on SDS-PAGE similar to hLA-ext shown in (A).
doi:10.1371/journal.pone.0026093.g003
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at pH 3.9 and purified by ammonium sulfate precipitation. Since
the thrombin cleaved Alexa Fluor 488 conjugated C-terminal
extension peptide could not be analyzed by MALDI-TOF, a
fluorescence emission at 488 nM from the Alexa Fluor 488
conjugated hLA-ext protein samples were analyzed on SDS-
PAGE gel, with and without thrombin treatment. Only a
fluorescence emission from the protein band that was not treated
with thrombin is observed, suggesting that the Alexa Fluor 488
molecule is conjugated to the C-terminal extension peptide of the
glycosylated hLA-ext protein (Figure 4C). Similarly, the aD-hLA-
ext protein is also conjugated with aminooxy-Alexa Fluor 488
molecule after glycosylating with C2-keto-Gal molecule.
Glycosylated hLA-ext and aD-hLA-ext proteins coupled to
aminooxy-biotin molecule were analyzed on non-reduced SDS-
PAGE (Figure 5A and B). Various amounts of biotin conjugated
protein samples with and without thrombin treatment were run
on non-reduced SDS-PAGE gel and transferred to a membrane.
The biotin conjugated proteins were detected by streptavidin-
HRP and chemiluminescence substrate. Only samples that were
not treated with thrombin showed a chemiluminescence band at
the expected molecular weight, indicating that these proteins
could also be site-specifically biotinylated in the C-terminal
extension peptide.
HAMLET preparation and characterization
HAMLET has been traditionally prepared by passing the
apoprotein through an OA-conditioned anion exchange chro-
matographic column [16]. Recently, Kamijima et al. have used a
method for preparing HAMLET that involves mixing and heating
the OA with the native protein [30] and confirmed by others [31].
We followed the heating method for the complexation with OA
but used the Ca
2+-depleted hLA (apoprotein) instead of Ca
2+-
bound hLA (holo form) during heating for 10 min at 60
oC.
Protein was estimated by the Bradford method, and fatty acid
content was determined using liquid chromatography coupled to a
mass spectrometer (Figure 6). Two forms were tested: the molten
globule hLA (mg-hLA) and the aD-hLA complexed with OA. The
protein to OA molar ratios on various samples were determined by
LC-MS studies and listed in Table 1. Previously, Petterson-
Kastberg et al. [32] investigated the ratio of protein to OA in
HAMLET, and, although the method for preparing HAMLET
was the conditioned column, their ratio seems to agree with the
results reported here. Using
1H NMR spectroscopy, a-LA to OA
ratio of 1:5.4 was observed in HAMLET, and for rhLA
all-Ala to
OA, ratios were 1:7.3 (using chemical analysis) and 1:9.5 (using
1H
NMR spectroscopy) [32]. In our current study all the protein-OA
complexes are made with 1:10 ratio and the protein to OA ratio
determined by the LC-MS method is comparable to the values
Figure 4. Site-specific labeling with aminooxy-Alexa Fluor 488 of hLA-ext. The hLA-ext protein (A) is glycosylated by the ppGalNAc-T2
enzyme in the presence of Mn
2+ and UDP-C2-keto-galactose. The lower panel shows the MALDI-TOF analysis of the C-terminal extension peptide
released upon thrombin cleavage. (B) The glycosylated hLA-ext protein with a single C2-keto-Gal molecule (blue circle) is conjugated with the
aminooxy-Alexa Fluor 488 molecule. The lower panel shows the MALDI-TOF spectrum of the glycosylated C-terminal extension peptide released after
thrombin treatment of the glycosylated hLA-ext protein. The increased molecular weight of 201 Da corresponds to a single C2-keto-gal molecule.
Since the Alexa Fluor 488 conjugated C-terminal peptide released from the Alexa Fluor 488 conjugated hLA-ext protein could not be observed on a
MALDI-TOF spectrum, the protein with and without thrombin treatment was analyzed on a SDS-PAGE gel (C) for the fluorescence emission detection
(lower panel). Fluorescence emission from the protein band is only observed when the protein was not treated with the thrombin, suggesting that
the Alexa Fluor 488 molecule is conjugated to the C-terminal extension peptide.
doi:10.1371/journal.pone.0026093.g004
Studies with Site-Specific Labeled HAMLET
PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e26093found by others. Thus the presence of the C-terminal extension
with a sugar or sugar conjugated with Alexa fluoro probe does not
significantly affect the protein to OA ratio. However, when the
complex is made with higher amount of OA (1:100) the protein-
OA complex could not be precipitated with 1M sodium chloride
and purified easily. Interestingly when the protein-OA complex is
prepared with 1:25 ratio, the purified complex had a ratio of 1:35
as determined by the LC-MS. This higher OA value suggests that
at higher OA concentrations the protein-OA complex associates
with OA and could not be easily purified.
Tumoricidal activity by the protein–OA complex
The tumoricidal activity of mg-hLA, mg-hLA–OA complex,
mg-hLA-ext, and mg-hLA-ext–OA complex was tested on several
tumor cell lines and on immortalized, non-transformed mammary
epithelial cell line MCF-10A (Table 2). Detailed studied were
carried out with SK-BR-3 and MDA-MB-468 cell lines. Viability
was investigated using Trypan blue and Annexin V methods.
SK-BR-3 cells (Figure 7) and MDA-MB-468 cells (data not
shown) were incubated for 3 h with 30 mM molten globule
proteins (mg-hLA or mg-hLA-ext) alone or in complex with OA
(1:10 ratio). Control cells were incubated with media only, and
their viability was considered to be as 100%. Control cells were
incubated with 300 mM OA alone. Three independent experi-
ments were performed, with results shown as mean 6 SEM
(*p,0.05) (Figure 7). When cells were incubated with the mg-hLA,
viability in the cell lines studied was comparable to the control
(media alone). The same results were obtained with the molten
globule protein of the modified hLA with a C-terminal extension
(mg-hLA-ext). When mg-hLA was complexed with OA in a 1:10
ratio, viability of the SK-BR-3 cell lines was reduced by 70%
(Figure 7A). The same effect was observed with the complexes
Figure 5. Site-specific labeling of proteins with aminooxy-biotin. Glycosylated proteins of hLA-ext (A) and aD-hLA-ext (B) were coupled with
aminooxy-biotin. Proteins were separated on SDS- PAGE and transferred to the nitrocellulose membrane. Biotinylated proteins were detected with
streptavidin-HRP and chemiluminescent substrate. Biotinylated HAMLET retained cytotoxic activity (data not shown).
doi:10.1371/journal.pone.0026093.g005
Figure 6. Liquid chromatography–mass spectrometry (LC-MS)/Single Ion Monitoring (SIM) chromatogram. Representative Profile for
the Oleic Acid-Protein Complex and its 18 C
13 isotopic Oleic Acid Internal Standard (ISTD). The original Complex was diluted 60 times with ISTD at
0.5 mg/mL. 25 mL sample solution was injected on to the column.
doi:10.1371/journal.pone.0026093.g006
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portion of the hLA does not interfere with its tumoricidal activity
(Figure 7A). Incubation with OA alone had a mild influence on the
viability of the SK-BR-3 cells. Similar results were obtained with
the MDA-MB-468 cells (data not shown). The tumoricidal activity
was studied using Annexin V-FITC staining of the cell lines SK-
BR-3 (Figure 7B) and MDA-MB-468 (data not shown) after
exposure to hLA in a molten globule state complexed with OA.
Cells were incubated for 1 h with 30 mM protein and then stained
according to the manufacturer’s protocol. Five-thousand events
were analyzed by flow cytometry. Phosphatidylserine exposure
(detected cell surface by Annexin V binding) was higher in cells
incubated with OA complexes derived from mg-hLA and mg-
hLA-ext than that in cells incubated with protein without complex
with OA or media alone, as evidenced by the shift in fluorescence
emission (Anexin V-FITC). In conclusion, the OA complexes of
both mg-hLA and mg-hLA-ext-showed comparable tumoricidal
activities. The addition of a 17–amino acid C-terminal tag to hLA
doesn’t affect its biological activity when complexed with OA,
making it a suitable substrate for subsequent labeling.
In addition, we have tested other human cell lines, Jurkat (T-cell
lymphoma), A549 (lung adenocarcinoma), MCF-7 (breast adeno-
carcinoma), U-87 (glioblastoma), and HeLa (cervical adenocarci-
noma) (data not shown), and studied the specificity of the complex
toward tumor cell lines and the MCF-10A immortalized, non-
transformed mammary epithelial cells. We found the complex is
not cytotoxic when MCF-10A cells were cultured to confluence
(data not shown), as previously described for other non-tumor cells
[14].
Confocal microscopy studies
For confocal microscopy studies, we labeled the C-terminal
extension of hLA-ext first with C2-keto-Gal and then conjugated it
with Alexa Fluor 488 (Figure 4). The labeled complex tested on
A549 cells showed tumoricidal activity (Figure 8A).Using the
labeled complex or molten globule protein alone; we studied
internalization of the mg-hLA-ext by fluorescence confocal
microscopy on an MCF-7 cell line (Figure 8). We found that the
Alexa Fluor 488–labeled mg-hLA-ext when complexed with OA
(Figure 8C) internalizes to cytoplasm and cell nuclei, while the
Alexa Fluor 488–labeled molten globule protein of hLA-ext alone
was not internalized (Figure 8B).
The internalization process could be followed by live confocal
microscopy on SK-BR-3 cells (Figure 8D). SK-BR-3 cells were
treated with mg-hLA-ext-Alexa Fluor 488/OA (green). Nuclei
were stained in blue with Hoechst 33342. With time, the complex
bound to the cell membrane and was internalized. Accumulation
of a green fluorescent signal could be detected in the cytoplasm
and cell nuclei. The DNA was fragmented when this process
occurred, and chromatin was seen on the nuclear margins. Inside
the cell nucleus, an accumulation of green fluorescent signal at
defined structures was seen.
In a different study, co-localization of the green fluorescent
signal corresponding to the complex and fibrillarin protein was
found at the cell nuclei in SK-BR-3 cells (Figure 9) and MDA-MB-
468 cells (data not shown) treated with mg-hLA/OA complex.
a-Domain hLA (aD-hLA)
Alpha domain of hLA (aD-hLA) with and without OA complex
were tested on SK-BR-3 cells and MDA-MD-468 cells (data not
shown) and biological activities were observed using Trypan Blue
and Annexin V (Figure 10 A and B). The aD-hLA and aD-hLA
with extension (aD-hLA-ext) complexed with OA showed
comparable tumoricidal activities, indicating that the beta domain
of hLA is not required for the complex to acquire cytotoxic
properties. The aD-hLA-ext was glycosylated, labeled with Alexa
Fluor 488, and complexed with OA. To visualize the internali-
zation of this alpha domain–derived complex, cells were incubated
with labeled proteins, with (Figure 10D) and without (Figure 10C)
complexation with OA and fixed. Nuclei were stained with
Hoechst 33342. Only complexed protein was internalized after
3 h of incubation. These results indicate that we have been
successful in expressing, labeling, and imaging, by confocal
microscopy, a reduced size HAMLET-like molecule.
Discussion
Since the discovery 16 years ago of HAMLET [14], a
tumoricidal complex originally isolated from human milk,
investigators have been challenged to deepen the knowledge of
its nature. Extensive work has already been achieved, such as
defining the need for both components, the molten globule state of
a-LA and OA as a lipid cofactor, and defining the cellular targets,
which include mitochondria [17], proteasomes [20], nuclei
[33,34], lysosomes [35], and the cell membrane [21]. Still, many
aspects remain unexplained, such as HAMLET’s specificity for
tumor cells, the possible presence of a HAMLET receptor,
possible mechanism of action, and the nature of the complex’s
structure.
Studies have shown that a-LA without any disulfide bond,
where all the cysteine residues are mutated to alanine residues, or
Table 1. Oleic acid content determined from the HAMLET
preparations using LC-MS method.
Protein Protein to OA ratio
Used to make
HAMLET
Determined by
LC-MS method
aD-hLA 1:10 1 :10.4
mg-hLA 1:10 1:8.2
mg-hLA-ext 1:10 1:9.2
mg-hLA-ext 1:25 1:34.5
mg-hLA-ext-keto 1:10 1:6.1
mg-hLA-ext-keto-Alexa Fluor 488 1:10 1:7.1
doi:10.1371/journal.pone.0026093.t001
Table 2. Cell lines tested for the tumoricidal activity with
HAMLET prepared with hLA-ext in 1:10 oleic acid ratio.
Cell lines
Tumoricidal activity
HAMLET
SK-BR-3 (breast adenocarcinoma) +
MDA-MB-468 (breast adenocarcinoma) +
Jurkat (T-cell lymphoma) +
A549 (lung adenocarcinoma) +
MCF-7 (breast adenocarcinoma) +
U-87 (glioblastoma) +
HeLa (cervical adenocarcinoma) +
MCF-10A (immortalized, non-transformed mammary
epithelial cells)
-
doi:10.1371/journal.pone.0026093.t002
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tumoricidal complex with OA [32,36]. Earlier protease digestion
and spectroscopic studies on the molten globule state of a-LA
indicated that the b-domain of the protein may be more
disordered than the a-domain [37]. Furthermore, the deletion of
the b-domain from a-LA has been shown to have little impact on
the tertiary structure of the a-domain [29]. Therefore, we have
chosen the a-domain of the hLA protein for further investigation
in the present study. Like the full-length protein, the a-domain,
after refolding also remained a monomer and formed a
tumoricidal complex with OA.
In all studies, the molten globule state of the a-LA was found to
be essential for forming a tumoricidal complex with OA. It has
been shown that, in the molten globule state a-LA is more
hydrophobic compared to its holo-form [38]. Thus, this state may
facilitate the binding of the fatty acids, such as OA. A simple
addition of OA to the molten globule a-LA solution may not be
enough to make the complex, as most OA molecules exist as
micelles in water. Simple heating of such a solution may disrupt
the micelles enough to cause a few OA molecules to dissociate and
bind to a molten globule a-LA molecule, thus generating a
HAMLET molecule. Although, it may be hard to predict how
many OA molecules may be bound to the hydrophobic surface of
a a-LA molecule, the number we have determined in our complex
is comparable to the ones reported by others.
We have earlier developed a site-specific labeling technique of
proteins. In this technique, the target protein is made with a C-
terminal 17–amino acid fusion peptide. This peptide contains a
single Thr residue to which a C2-keto-galactose sugar is
transferred from its UDP-derivative by the ppGalNAc-T2 enzyme
[26]. Since the glycosylated protein carries a unique chemical
handle at its sugar moiety, it can be used for site-specific
Figure 7. Measurement of tumoricidal activity during conversion of recombinant protein to tumoricidal complex. The effect on the
cell viability of SK-BR-3 cells was studied after treatment with mg-hLA, mg-hLA/OA, and mg-hLA-ext and mg-hLA-ext/OA. The cells were incubated
with molten globule proteins alone or complexed with OA, and their viability was investigated using Trypan blue (A) and by FACS analysis with
Annexin V (B). When cells were incubated with the apo-form of hLA (mg-hLA and mg-hLA-ext), viability was comparable to the control (media alone)
in the cell lines studied. When molten globule protein derived from hLA or hLA-ext was complexed with OA in a 1:10 ratio, viability of the cell lines SK-
BR-3 was reduced. Results are shown as mean 6 SEM (*p,0.05).
doi:10.1371/journal.pone.0026093.g007
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PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e26093Figure 8. Microscopy studies using site-specific-fluoroprobe-labeled protein. (A) Tumoricidal activity of the labeled protein hLA-ext in
molten globule state was tested on A549 cells. MCF-7 cells were incubated for 4 h, with 30 mM Alexa Fluor 488-labeled mg-hLA-ext protein alone (B)
or complexed with OA (C). After treatment, cells were fixed and nuclei were stained with vital stain Hoechst 33342 (blue). When complexed with OA,
Alexa Fluor 488 labeled mg-hLA-ext (green) internalizes to cytoplasm and cell nuclei, while molten globule protein alone did not enter the cells. (D)
Confocal images of SK-BR-3 cells treated with Alexa Fluor 4888-labeled mghLA-ext complexed with OA at the indicated times.
doi:10.1371/journal.pone.0026093.g008
Figure 9. Aggregates in the nuclei co-localize with a nucleolus marker. SK-BR-3 cells were treated with Alexa Fluor 488 labeled mg-hLA-ext
complexed with OA or without OA (control) for 4 h, fixed, permeabilized, incubated with a-fibrillarin monoclonal antibody, and detected with anti-
mouse-Alexa Fluor 555–labeled antibody (red). In cells treated with OA complex, co-localization of green fluorescent signal and fibrillarin protein was
found at the cell nuclei in SK-BR-3 and MDA-MD-468 (data not shown) cell lines.
doi:10.1371/journal.pone.0026093.g009
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present study, extending the a-LA with C-terminal fusion peptide
was not expected to alter its biological activity, since a-LA from rat
naturally exists with an 11–amino acid C-terminal extension [23].
The labeling was carried out before the OA complex was formed.
We have observed that the native hLA with the N-terminal his-tag
readily binds to a metal affinity column; however, after the OA
complex is made, the protein does not bind to the metal affinity
column. Therefore, the C-terminal labeling was carried out prior
to making the OA complex. Furthermore, the C-terminal
extension of the native a-LA by itself does not affect its activity
either as lactose synthase (data not shown) or, as shown in the
present study, as a HAMLET, indicating that the protein with the
C-terminal extension carrying the bulky fluoroprobe can still be
converted into tumoricidal complex.
Fluoroprobe-labeled and complexed molten globule protein was
used for live-/fixed-cell imaging. Alexa Fluor 488 signal could be
detected at the cell surface and, with time, accumulating at the cell
nucleus, as shown by Hakansson et al. [33]. Moreover, we have
identified a subnuclear structure in which the green fluorescent
signal of Alexa Fluor 488 accumulated in nucleoli, using anti-
fibrillarin antibody. The significance of co-localization of a labeled
complex with cell nucleoli is unknown. However, a variety of
molecules that apparently have no role in ribosome assembly, have
been found at nucleoli [39]. In addition, one study has suggested
that unfolded proteins are stored in the nucleolus during stress [40].
In addition to using site-specific labeling for microscopy studies,
we have shown that the site-specific biotin coupling could also be
achieved, suggesting a potential application for ultra-structural
studies, such as transmission electron microscopy. Biotinylated
protein could be used to ‘‘fish-out’’ cancer cell surface ligands
interacting with HAMLET. These specific interactions between
the cell surface ligand(s) and HAMLET may be enough to initiate
the apoptotic process(es) leading to tumor cell death.
In conclusion, we have been successful in adding a chemical
handle to HAMLET without affecting its biological activity,
allowing us to trace the complex at the cell surface or inside the
cell. The addition of a site-specific handle to a tumoricidal
complex could be further exploited for isolation of partner/target
molecules, providing insight into the tumor specificity of the
complex.
Materials and Methods
Cloning, expression, and refolding of hLA, hLA-ext, T-hLA,
T-hLA-ext, and His-hLA
The human a-LA gene was cloned from a mammary gland
cDNA library (Clontech, Mountain View, CA) into Nde I and
Figure 10. Reduced size HAMLET has comparable properties to complex derived from full-length protein. aD-hLA in complex with OA
has biological properties that are similar to mg-hLA OA complex with cancer cell lines SK-BR-3 and MDA-MD-468 (data not shown). aD-hLA and aD-
hLA-ext, complexed with OA have comparable tumoricidal activities measured by Trypan Blue (A) and by FACS analysis using Annexin V (B),
indicating that the b-domain of hLA is not required for the complex to acquire cytotoxic properties. SK-BR-3 cells were incubated with Alexa Fluor 488
labeled aD-hLA-ext either alone (C) or as OA complex (D) for 3 h. The cells were then fixed with 4% PFA in PBS, and the nuclei were counterstained
with Hoechst 33342 (blue). Only aD-hLA-ext-Alexa Fluor 488 (green signal) complexed with OA is internalized by the cells.
doi:10.1371/journal.pone.0026093.g010
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pETnef, similar to mouse a-LA as described earlier [27]. The
hLA-ext and hLA with N-terminal Histidine-tag (His-hLA) were
constructed in Nde I and EcoR I restriction sites of the pETnef
vector, similar to the glutathione S-transferase protein with the
same C-terminal extension, as described previously [26]; the
deletion of the b-domain in the human a-LA, the aD-hLA, was
constructed as described previously [28]; the construction of aD-
hLA with C-terminal extension (aD-hLA-ext) was similar to the
previously published method [26]. From 1 L of bacterial culture,
15 mg of aD-hLA, and 5.32 mg of aD-hLA-ext were obtained.
All the clones were sequenced and transfected into BL21
DE3LysS cells for protein expression. The expression and
refolding of these proteins were carried out under conditions
similar to those described previously for mouse a-LA [27,28].
Nearly 5 mgs and 6 mgs, of purified protein were obtained from 1
L of bacterial culture for hLA and hLA-ext, respectively. For His-
hLA purification, after folding protein was dialyzed first against
10 mM Tris-HCl (pH 8.0) and then against PBS, and next
purified using TALON metal affinity resin (Clontech). Protein was
eluted from the column in PBS buffer containing 1 M NaCl and
100 mM imidazol (pH 7.4). Elution buffer was removed by
dialysis against 20 mM Tris-HCl (pH 8.0).
Confirmation of the C-terminal extension with thrombin
cleavage
Seventeen micrograms of purified hLA-ext was incubated
overnight at room temperature with one unit of thrombin from
human plasma from Sigma-Aldrich (St Louis, MO) in a thrombin
reaction buffer (10 mM Tris-HCl (pH 8.0), 2 mM CaCl2, and
150 mM NaCl). Equal amounts of cut and uncut proteins were
analyzed by 18% SDS-PAGE and by mass spectrometry.
Circular dichroism spectroscopy
Near (320 to 250 nm) UV circular dichroism spectroscopy (CD)
spectra were measured with AVIV Mod.202 CD Spectrometer
Aviv Instruments (Lakewood, NJ) with a 10-mm light path CD
UV Hellma quartz cell (Plainview, NY). The protein concentra-
tion was measured by absorbance at 280 nm. All measurements
were made at 25
oC. The wavelength step was 1 nm, with response
time 5 sec; one scan was performed, and the waiting time was
0.5 sec. The spectrum of the pure buffer was subtracted from the
protein spectra. The molar ellipticity T (mdeg x cm
2 x dmol
21)
was calculated from milidegree, the number of amino acids (aa),
protein concentration (c, in molar units), and cell length (l, in cm)
as T = milidegrees/ (aa x c x l).
a-Lactalbumin conjugation and labeling
Recombinant ppGalNAcT2 enzyme was prepared as previously
described [5].Forty mg of hLA-ext was glycosylated with 20 mgo f
ppGalNAc-T2 overnight at room temperature in the presence of
25 mM Tris-HCl (pH 8.0), 10 mM MnCl2, and 0.5 mM UDP-
C2-keto-Gal in a total volume of 100 mL. To label hLA-ext with
the fluorescent probe, 7 mL of 10 mg/ml C2-keto-Gal glycosylated
hLA-ext protein were labeled in a 40-mL volume containing
166 mM sodium acetate, pH 4.9, and 0.675 mg/ml aminooxy-
Alexa Fluor 488 (Invitrogen, Carlsbad, CA). The reaction mixture
was incubated overnight in the dark, at room temperature, in a
rocking platform. Excess Alexa Fluor 488 was removed by
ammonium sulfate precipitation of the labeled protein. Excess
ammonium sulfate was removed by washing with 20 mM Tris
(pH 8) in 10,000 MWCO centrifugal filters (Amicon, Co. Cork,
Ireland). To verify that labeling occurred in the extension
sequence of hLA-ext, a 200 fold dilution of the labeled hLA-ext
was incubated with thrombin for 48 h. Cut and uncut protein
samples were electrophoresed on 14% SDS-PAGE gel. A
fluorescence signal was detected in a Hitachi FMBIOII Multi-
View scanner with a 505-nm filter.
To label hLA-ext and aD-hLA-ext with biotin, 2.3 mg of C2-
keto-Gal glycosylated hLA-ext and aD -hLA-ext proteins were
labeled in a 300-ml volume containing 166 mM sodium acetate,
pH 4.9, and 3 mM aminooxy-biotin (Dojindo Laboratories,
Japan). The reaction mixture was incubated overnight at room
temperature. Excess biotin was removed by washing with 20 mM
Tris-HCl (pH 8.0) in Amicon Ultra centrifugal filters with 10,000
MWCO for hLA-ext, and 3,000 MWCO for aD-hLA-ext
(Millipore, MA).
To detect the labeled protein, 10-, 50-, and 80-ng samples were
separated on an SDS-PAGE. Protein was transferred to a
nitrocellulose membrane (Invitrogen), blocked with 5% nonfat
dry milk, 0.2% Tween 20 for 1 h at room temperature, and
incubated for 1 h with 1:4000 diluted streptavidin conjugated with
horseradish peroxidase (GE Healthcare, Piscataway, NJ) in a PBS
solution containing 3% BSA and 0.02% Tween 20. After four 5-
min washes with blocking solution, the membrane was incubated
with HRP substrate ECL Western Blotting Analysis System (GE
Healthcare) and exposed to Kodak BioMax light film. To detect
the labeling in the extension tag, samples were treated with
thrombin. Control samples remained untreated. Labeled hLA-ext
was converted to molten globule and complexed with OA as
described below.
Preparation of hLA–OA, unlabeled and labeled hLA-ext–
OA complexes
a-LA–OA complexes were prepared by the method described
by Kamijima et al. [30], with following modification: briefly, a
210-mM solution of recombinant hLA was incubated overnight
with 5 mM EGTA and dialyzed against 5 mM EGTA/20 mM
Tris-HCl (pH 8.0) at room temperature to remove calcium.
EGTA was removed by a second dialysis overnight at room
temperature against 20 mM Tris-HCl (pH 8.0).
OA (Fluka, Buchs, Switzerland) was initially dissolved in 20%
ethanol/80% 20 mM Tris-HCl (pH 8.0) solution and further
diluted in 20 mM Tris-HCl (pH 8.0) buffer to give a 24-mM stock
solution of OA. A solution of the molten globule protein (210 mM)
in 20 mM Tris-HCl (pH 8.0) was mixed with OA stock solution
(in a 1:10 molar ratio of protein to OA), heated for 10 min at
60
oC, and cooled to room temperature. Excess OA was removed
by mild centrifugation. Further, protein (complexed or molten
globule alone) was precipitated with NaCl (final concentration 1M)
and adjusted to a final pH of 3.5 with 1 M HCl. After 4 h on ice or
overnight at 4
oC, the precipitated complex was re-dissolved in
20 mM Tris-HCl (pH 8.0) and dialyzed overnight against 20 mM
Tris-HCl (pH 8.0) to remove excess NaCl. For His-hLA samples,
after removal of calcium, complexation with OA was performed as
described above.
Determination of protein to OA ratio
Protein concentration of the complex was determined by the
Bradford method, and OA concentration was determined by HPLC-
ESI-MS/MS technique using a HPLC (Agilent 1100 series) coupled
to triple quadrupole mass spectrometer (TSQ Quantum Discovery
Max from Thermo Scientific) utilizing the single-ion monitoring
technique in negative ionization mode [41]. For quantitation of OA,
stable isotopic OA containing 18 [
13C]-labeled carbon atoms was used
as the internal standard, and was purchased from Cambridge Isotope
Laboratories (Andover, MA). OA was monitored at m/z 281.2, and
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solution of neat OA was made in 1/1 v/v water:MeOH at 0.01, 0.1,
1, 5, 10, 50, and 100 mg/ml levels containing 0.5 mg/ml internal
standard. At the 100 mg/ml calibration level, the peak saturation
occurs. 16.67 ml of original protein-OA solution was diluted 60 times
to give 1 ml of sample solution that also contained 0.5 mg/ml of
ISTD. For quantitative analysis, 25 ml of calibrator or protein-OA
sample solution was injected into a LC-MS system comprised of a
capillaryLC column (SupelcoC18column(50 mm60.5 mm65 mm),
Sigma) coupled via electrospray to a triple quadrupole mass
spectrometer utilizing single ion monitoring technique (SIM) in
negative ionization mode, monitoring OA at m/z 281.2, and the
internal standard (ISTD) at m/z 299.3. The protein-OA sample was
run in triplicate. A linear calibration curve with a weighting index of
1/X was used, and an R
2 of 0.9999 was observed.
Cell culture
Human lung adenocarcinoma cells A549 were cultured in
RPMI-1640 medium (HyClone, Thermo Fisher, Logan, UT)
supplemented with 2 mM glutamine, 100 IU/ml penicillin-
100 mg /ml streptomycin (HyClone), 50 mg/ml gentamicin
(Gibco/Invitrogen, Grand Island, NY), 1% non-essential amino
acids (HyClone), and 10% (v/v) fetal bovine serum (FBS, Gibco).
SK-BR-3 and MDA-MB468 cells were cultured in McCoy’s 5A
media (Gibco) supplemented with 10% FBS and antibiotics. MCF-
7 cells were grown in RPMI 1640 (Gibco) and supplemented with
10% FBS and antibiotics.
MCF-10A immortalized, non-transformed mammary epithelial
cells (obtained from Dr. Esta Sterneck’s laboratory, NCI-
Frederick) were cultured in DMEM/F-12 1:1 (Gibco) supple-
mented with 100 IU/ml penicillin- 100 mg/ml streptomycin
(HyClone), FBS, 10 mg/ml insulin (Sigma), 100 ng/ml Cholera
toxin (Calbiochem, La Jolla, CA), 0.5 mg/ml Hydrocortisone
(Sigma), 20 ng/ml EGF (Invitrogen) and 1 mM CaCl2.
Cell death assay
Cell viability was determined using the Trypan blue exclusion
m e t h o d .C e l l s ,5 x 1 0
4 cells per well, were plated in a 48-well plate
(Corning Incorporated, Corning NY). After 24 h, media was removed
and replaced with fresh media without FBS, and the different protein/
protein complexes were added and incubated for the indicated lengths
of time. Cells were incubated with 30 mM molten globule protein
alone or complexed with OA for 3 h (the first hour of incubation was
without FBS). After treatment, floating cells from conditioned media
and trypsinized cells were pooled and pelleted. Cells were resuspended
in 50 mL of PBS, and the cell suspension was mixed with an equal
volume of 0.4% Trypan blue stain (G i b c o ) .C l e a r ,v i a b l ec e l l sw e r e
counted microscopically in Kova glasstic slides with grid chamber
(Hycor, Garden Grove, CA). Cell number is expressed as a percentage
of the untreated control cells.
For Annexin V detection, cells were incubated with 30 mM
molten globule protein alone or complexed with OA. After
treatment, floating and trypsinized cells were pelleted and washed
once with binding buffer and stained with Annexin V-FITC
(ApoAlert, Clontech, Mountain View, CA) according to the
manufacturer’s instructions. Cells were quantified in a Becton
Dickinson FACScalibur cytometer and CellQuest software.
Confocal fluorescence microscopy
Cells were plated on an 18-well slide (ibiTreat, Ibidi Integrated
BioDiagnostics, Munich, Germany) and grown for 2 nights (2000
cells/well). Media was replaced with mg-hLA complexed with OA
(20 mM unlabelled or 10 mM labeled); or mg-hLA alone (20 mM
unlabelled or 10 mM labeled) and cells were then incubated at 37uC
inmediawithout serum. Same procedurewas followed foraD-hLA.
For anti-fibrillarin staining, cells were incubated for 4 h, and
then slides were fixed for 15 min with 4% paraformaldehyde in
PBS. After rinsing with PBS, cells were permeabilized in a PBS
solution containing 0.1% TritonX-100, 2 mg/ml BSA, and 1 mM
sodium azide for 5 min, and then blocked for 1 h in a PBS
blocking solution (0.05% Tween 20, 2 mg/ml BSA, 1 mM sodium
azide). Samples were incubated overnight with anti-fibrillarin
mouse monoclonal antibody (Invitrogen), 1:500, in blocking
solution at room temperature in a humidified chamber. After
3610-min wash, the sample was incubated with 1:1000 anti-
mouse-Alexa Fluor 555 antibody (Invitrogen) in blocking solution.
Following the washes, nuclei were stained with Hoechst 5 mg/ml
for 15 min, and slides were mounted with mounting media (Ibidi).
Confocal microscopy studies were performed with an Olympus
Fluoview 1000 inverted microscope with lX81. Olympus FV100
2.0c and FV-ASW 1.6 viewer software were used for acquisition
and analysis, respectively.
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